Last Posted: Apr 16, 2020
- Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia
NHLBI funding announcement, April 2020 - Lipoprotein(a) and COVID-19
S Seim, Th FH FOundtaion, April 8, 2020 - Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk.
Vuorio Alpo et al. Journal of internal medicine 2020 Apr - Awareness of Familial Hypercholesterolemia Among Healthcare Providers Involved in the Management of Acute Coronary Syndrome in Victoria, Australia.
Mirzaee Sam et al. CJC open 2019 Jul 1(4) 168-172 - Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia.
Brown Emily E et al. Journal of clinical lipidology 2020 Mar - Perspectives from individuals with familial hypercholesterolemia on direct contact in cascade screening.
Schwiter Rachel et al. Journal of genetic counseling 2020 Mar - Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels.
Bianconi Vanessa et al. Trends in cardiovascular medicine 2020 Mar - Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal Frederick J et al. The New England journal of medicine 2020 Mar - Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
Luirink Ilse K et al. Atherosclerosis 2020 Feb 29924-31 - Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score.
Gao Weiqi et al. Journal of Cancer 2020 11(9) 2509-2517
No hay comentarios:
Publicar un comentario